Form 8-K - Current report:
SEC Accession No. 0001628280-24-003304
Filing Date
2024-02-05
Accepted
2024-02-05 16:16:37
Documents
16
Period of Report
2024-02-05
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K xcur-20240205.htm   iXBRL 8-K 24130
2 EX-99.1 a8kbluejay-exhibit991.htm EX-99.1 8796
6 exicureimage1a10.gif GRAPHIC 2794
  Complete submission text file 0001628280-24-003304.txt   164561

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xcur-20240205.xsd EX-101.SCH 1907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xcur-20240205_lab.xml EX-101.LAB 23834
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xcur-20240205_pre.xml EX-101.PRE 12512
17 EXTRACTED XBRL INSTANCE DOCUMENT xcur-20240205_htm.xml XML 2706
Mailing Address 2430 N. HALSTED ST. CHICAGO IL 60614
Business Address 2430 N. HALSTED ST. CHICAGO IL 60614 847-673-1700
EXICURE, INC. (Filer) CIK: 0001698530 (see all company filings)

EIN.: 815333008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39011 | Film No.: 24595920
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)